HC Wainwright Boosts Spectrum Pharmaceuticals (SPPI) Price Target to $33.00

Spectrum Pharmaceuticals (NASDAQ:SPPI) had its price objective raised by HC Wainwright to $33.00 in a report released on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 57.22% from the company’s current price.

Other research analysts have also issued reports about the stock. B. Riley initiated coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, December 18th. They issued a “buy” rating and a $26.00 target price for the company. Guggenheim initiated coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, October 23rd. They issued a “buy” rating and a $32.00 target price for the company. Jefferies Group upped their target price on shares of Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 20th. BidaskClub lowered shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Zacks Investment Research upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.83.

Spectrum Pharmaceuticals (NASDAQ SPPI) opened at $20.99 on Monday. Spectrum Pharmaceuticals has a 1 year low of $4.86 and a 1 year high of $23.50. The stock has a market cap of $2,110.00, a price-to-earnings ratio of -20.99 and a beta of 1.64. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.04 and a quick ratio of 4.89.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Spectrum Pharmaceuticals during the third quarter valued at about $152,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Spectrum Pharmaceuticals during the third quarter valued at about $177,000. Campbell & CO Investment Adviser LLC purchased a new stake in Spectrum Pharmaceuticals during the third quarter valued at about $192,000. Crossmark Global Holdings Inc. purchased a new stake in Spectrum Pharmaceuticals during the third quarter valued at about $212,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in Spectrum Pharmaceuticals during the second quarter valued at about $114,000. Institutional investors and hedge funds own 71.77% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Boosts Spectrum Pharmaceuticals (SPPI) Price Target to $33.00” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/02/07/hc-wainwright-boosts-spectrum-pharmaceuticals-sppi-price-target-to-33-00.html.

Spectrum Pharmaceuticals Company Profile

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Analyst Recommendations for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit